Full-Time

Forecasting Operations & Insights Director

AbbVie

AbbVie

10,001+ employees

Global biopharmaceutical company developing medicines

No salary listed

Vernon Hills, IL, USA

Hybrid

Hybrid role; on-site in Mettawa, Illinois, USA.

Bachelor's, Master's, PhD

Category
Business & Strategy (1)
Required Skills
Forecasting
Machine Learning
Data Analysis

Get referred to AbbVie

See people who can refer or advise you

Requirements
  • Bachelor's degree in a quantitative, technical field (Finance, Economics, Data Science, Engineering, Life Sciences, or related); advanced degree strongly preferred.
  • 12+ years of relevant experience in the pharmaceutical, biotech, or life sciences industries in quantitative or analytical roles.
  • 12+ years of direct forecasting experience, including hands-on development, maintenance, and operation of forecasting or related analytical models.
  • Experience leading a multi-level team, setting direction for team leads and holding them accountable for their outputs.
  • Ability to lead across multiple team functions/disciplines, some outside of traditional commercial forecasting & finance.
  • Experience integrating analytical or operational team outputs with corporate planning processes, financial cycles, or other enterprise functions with defined timelines and downstream dependencies.
  • History of instilling a culture of quality and continuous improvement in teams they have led.
  • Strong working knowledge of pharmaceutical data sources (IQVIA TRx/NBRx, 852/867, patient flow, epidemiology) and their use in commercial decision-making.
  • Experience with statistical or AI-based forecasting methodologies and model governance.
  • Strong financial acumen, including understanding of how volume forecasts feed into finance and corporate planning processes.
  • Strong communication skills, including analytical storytelling, presentation development, and ability to translate technical outputs for non-technical audiences.
  • Demonstrated ability to influence and partner effectively across cross-functional teams in complex, matrixed organizations.
  • Excellent stakeholder management skills, including the ability to manage expectations and constructively engage forecasting and finance leaders.
Responsibilities
  • Owns the strategy and governance framework for AI/ML forecasting models maintained within the COE, ensuring responsible use, appropriate oversight, and continued performance integrity.
  • Leads the team in the ongoing operation, maintenance, and continuous improvement of AI/ML and statistical forecasting models developed through Finance Transformation and Forecasting Excellence initiatives.
  • Monitors model performance trends and determines when enhancements to algorithmic approaches are warranted as new data, methods, or capabilities become available.
  • Establishes and maintains guardrails and review processes governing the use of AI/ML forecasting tools across user teams, ensuring outputs are appropriately interpreted and applied.
  • Owns the COE’s technology roadmap for forecasting tooling, defining priorities for tool capability development in partnership with BTS and relevant technology stakeholders.
  • Leads the team in configuring and onboarding Forecast Horizon for new brands, therapeutic areas, and teams, ensuring consistent and high-quality implementation.
  • Partners with BTS and technology vendors to govern, maintain, and evolve forecasting system infrastructure.
  • Directs the team in developing purpose-built analytical tools to address specific forecasting needs across business units where the core platform requires supplemental support.
  • Brings relevant knowledge of the broader tooling landscape—to inform sound technology decisions when evaluating future investments.
  • Partners with cross-functional organizational stakeholders to define analytical priorities for the COE—determining which cross-portfolio, cross-TA, or pan-industry questions warrant centralized analytical investment.
  • Leads the team in executing high-priority analytical work to inform modeling of key organizational and market events, including: Analog research on launch, loss of exclusivity (LOE), label change, and access change events.
  • Leads the team in executing high-priority analytical work to inform modeling of key organizational and market events, including: Analysis of pan-industry events and their volume forecast implications (e.g., IRA policy impacts, macroeconomic shifts).
  • Leads the team in executing high-priority analytical work to inform modeling of key organizational and market events, including: Epidemiological and patient flow analyses to support new indication forecasting.
  • Synthesizes team outputs into guidance and frameworks that are usable and actionable for local forecasting teams.
  • Partners with the Director, Forecasting Standards & Training to ensure analytical insights continuously inform the evolution of forecasting best practices and standards.
  • Serves as an operational and quantitative resource for forecasters and finance leaders seeking guidance on tool utilization, data interpretation, and analytical methodology.
  • Leads the team in delivering consistent, high-quality support to Engagement Liaisons and the broader forecasting community, using stakeholder feedback to continuously refine operational COE priorities.
  • Contributes to cross-functional initiatives where quantitative forecasting support or scenario analysis is needed.
  • Leads a large, multi-disciplinary team organized across multiple specialized sub-functions—AI/ML and Statistical Forecasting, Forecast Horizon (Platform tool) Operation, and Forecasting Analytics & Insights—each with its own lead and direct reports.
  • Manages through a layer of directors and associate directors, providing leadership, strategic direction, and development support for functional leads accountable for their teams’ delivery.
  • Ensures team’s activities are well-integrated with AbbVie's corporate financial planning processes, so that functional outputs are coordinated, sequenced, and delivered in alignment with organizational timelines and stakeholder expectations.
  • Allocates resources and prioritizes work across a technically and functionally diverse portfolio spanning machine learning, statistical modeling, tool/platform operations, and quantitative analytics, balancing competing organizational demands with team capacity and development needs.
  • Provides regular feedback, coaching, and career development support to direct reports, fostering growth across a team with widely varied technical backgrounds and career trajectories.
  • Models AbbVie’s Ways of Working and fosters a team culture of rigor, accountability, and continuous improvement.
  • Identifies and implements structural changes to team design when needed to support the team’s mission as the COE evolves.
  • Reports to: Senior Director, Global Forecasting
  • Direct reports may include: Commercial AI/ML/Statistical Forecasting leads, Forecast Horizon Operations lead, Forecast Insights & Analytics lead
Desired Qualifications
  • Hands-on experience with purpose-built forecasting platforms (e.g., Forecast Horizon, ForecastPro, FlexiCast), providing grounded perspective on their relative strengths in an enterprise forecasting environment.
  • Experience with data engineering, visualization, or automation tools (e.g., SQL, Python, PowerBI, SAS).
  • Background in AI/ML and statistical model development, validation, or operationalization.
  • International or multi-geography commercial analytics experience across product lifecycle.
  • Experience managing team budgets, including vendor and technology spend, in alignment with team and enterprise priorities.

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • AbbVie raised 2026 revenue guidance to $67.6 billion after Q2 2026.
  • FDA review of SKYRIZI Crohn's subcutaneous induction targets a late-2026 approval.
  • WCLC 2026 data showed ABBV-1480 90% response in squamous NSCLC.

What critics are saying

  • HUMIRA revenue fell 36.1% in Q2 2026 as biosimilars keep taking share.
  • The Apogee deal cuts 2026 EPS by $0.14 and adds debt financing.
  • Epcoritamab missed the July 23, 2026 DLBCL endpoint, threatening future B-cell franchise growth.

What makes AbbVie unique

  • SKYRIZI and RINVOQ drove $8.8 billion of Q2 2026 immunology revenue.
  • Botox Cosmetic and Juvederm generated $973 million in Q2 2026 aesthetics sales.
  • Apogee purchase adds late-stage IL-13 and TSLP programs for eczema and asthma.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

3%

2 year growth

3%
Yahoo Finance
Aug 21st, 2026
AbbVie stock moves independently from market with 0.22 correlation driven by immunology drugs

AbbVie stock shows a correlation of just 0.22 to the S&P 500 over five years, meaning most of its movements stem from company-specific factors rather than broader market trends. The pharmaceutical firm's immunology segment generated nearly $8.8 billion of its $17 billion in second-quarter 2026 revenue, led by SKYRIZI at $5.5 billion and RINVOQ at over $2.5 billion. These treatments for chronic diseases have prices negotiated with payers, not consumers. AbbVie has delivered an annualised return of 21.5% with 23.5% volatility over five years, compared to the S&P 500's 12.9% return at 17.2% volatility. The company converts 28.3% of revenue into free cash flow, nearly double the S&P 500 median of 14.5%.

Grafa
Aug 21st, 2026
AbbVie reports 90% response in lung cancer study.

AbbVie reports 90% response in lung cancer study. * AbbVie reported a 90% objective response rate for ABBV-1480 plus platinum chemotherapy in squamous advanced NSCLC at the selected 10 mg/kg dose. * The same dose produced a 75.9% response rate in non-squamous disease and was selected as the recommended Phase 3 dose. * AbbVie will also present data for Temab-A and ABBV-706 across NSCLC and small cell lung cancer at the 2026 World Conference on Lung Cancer. AbbVie (NYSE:ABBV) reported Phase 1b lung cancer data showing objective response rates of 90% in squamous and 75.9% in non-squamous advanced NSCLC with ABBV-1480 plus platinum chemotherapy. At the 10 mg/kg dose, 27 of 30 patients with squamous disease and 22 of 29 with non-squamous disease achieved objective responses, according to the company. AbbVie said the findings support further evaluation of ABBV-1480 in advanced NSCLC and selected the 10 mg/kg regimen as the recommended Phase 3 dose. The company will present additional clinical results for telisotuzumab adizutecan, or Temab-A, in first-line non-squamous and EGFR-mutated NSCLC at the 2026 World Conference on Lung Cancer. AbbVie will also report ABBV-706 data in relapsed or refractory small cell lung cancer, including new safety analyses covering 240 patients. The company's conference presentations include real-world evidence evaluating SEZ6 as a potential therapeutic target in small cell lung cancer. The updates form part of AbbVie's clinical development program across non-small cell and small cell lung cancers, with several investigational therapies being evaluated across different treatment settings. Frequently asked questions. ABBV signals

Yahoo Finance
Aug 19th, 2026
AbbVie stock eyes breakout as Skyrizi dosing decision could unlock $24.5B revenue growth

AbbVie stock has returned 24.5% over the past three months, trading near its 52-week high. The pharmaceutical company's growth hinges on a pending regulatory decision for SKYRIZI, an immunology treatment that generates nearly a third of guided revenue. SKYRIZI sold $5.5 billion in Q2 2026, up 24% operationally. AbbVie guides the drug to $21.7 billion for 2026 against total company revenue of approximately $67.6 billion. The company has raised its 2026 guidance twice by $600 million combined. A subcutaneous induction option for Crohn's disease awaits regulatory approval this fall. Management expects the new dosing method to meaningfully accelerate SKYRIZI sales, though the commercial impact won't materialise until early 2027 due to contract timelines. Clinical trial results showed endoscopic response and remission rates 25 points above placebo.

BBC
Aug 19th, 2026
UK's Smith+Nephew CFO John Rogers to step down for external role.

UK's Smith+Nephew CFO John Rogers to step down for external role. August 19, 2026 The departure follows Smith+Nephew's decision weeks ago to cut its annual revenue growth forecast after second-quarter sales missed expectations due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing International News via Reuters: Smith+Nephew said on Wednesday its finance chief John Rogers would step down at the end of September to take up an external position in the United States, ending his roughly two-and-a-half-year tenure with the medical products company. Here are some more details: - The departure follows Smith+Nephew's decision weeks ago to cut its annual revenue growth forecast after second-quarter sales missed expectations due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing. - Smith+Nephew said it had appointed Senior Vice President Finance and Group Controller Pierre Palassian as interim chief financial officer until a permanent replacement was appointed. - Palassian, who joined Smith+Nephew in 2017, previously held senior roles at AbbVie and Abbott Laboratories. - Rogers, who took up the CFO role in early 2024, had relocated to the United States in 2025 for operational efficiencies. - Shares in the FTSE 100 company have gained nearly 14% during Rogers' tenure as CFO. - Smith+Nephew said Rogers would receive no severance payment, and that his outstanding incentive and share awards would lapse on September 30 under leaver rules. Reporting by Neeshita Beura in Bengaluru; Editing by Subhranshu Sahu - Advertisement - August 19, 2026 - Advertisement -

Yahoo Finance
Aug 15th, 2026
AbbVie shows strong cash flow margin of 34.8% but faces tepid revenue growth

AbbVie, the biopharmaceutical company spun off from Abbott Laboratories in 2013, has risen 9.7% to $249.64 per share over the past six months. The company generates $64.39 billion in revenue over the past 12 months, benefiting from significant economies of scale in its operations. AbbVie's free cash flow margin averaged 34.8% over the last five years, amongst the best in the healthcare sector. This strong cash generation enables reinvestment and capital returns to investors. However, the company's five-year annualised revenue growth of 3.7% remains tepid compared to sector peers. Despite this weakness, AbbVie's shares trade at 16.3 times forward price-to-earnings ratio. The company develops and markets medications for autoimmune diseases, cancer, neurological disorders, and other complex health conditions.